-
MAFLD predicts cardiovascular disease risk better than MASLD Liver Int. (IF 6.7) Pub Date : 2024-04-20 Ziyan Pan, Gamal Shiha, Gamal Esmat, Nahum Méndez‐Sánchez, Mohammed Eslam
Background and AimMetabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).MethodsSix thousand and ninety six participants from the 2017 to 2020 National
-
Delta virus infection and hepatocellular carcinoma Liver Int. (IF 6.7) Pub Date : 2024-04-18 Maurizio Bonacini
-
Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity Liver Int. (IF 6.7) Pub Date : 2024-04-18 Rachel B. Schenker, Christopher J. Machle, Kelsey A. Schmidt, Hooman Allayee, Rohit Kohli, Michael I. Goran
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common paediatric liver disease. Latinos have high MASLD risk due to 50% prevalence of GG genotype of PNPLA3. Our primary aim was to evaluate associations between dietary carbohydrates/sugars and liver stiffness in Latino adolescents with obesity. Our secondary aim was to examine effect modification by (a) PNPLA3 genotype
-
PRO‐C3, liver fibrosis and CKD: The plot thickens Liver Int. (IF 6.7) Pub Date : 2024-04-18 Amedeo Lonardo
-
-
Use of non‐invasive diagnostic tools for metabolic dysfunction‐associated steatohepatitis: A qualitative exploration of challenges and barriers Liver Int. (IF 6.7) Pub Date : 2024-04-18 Emmanuel A. Tsochatzis, Luca Valenti, Maja Thiele, Sophie Péloquin, Patrice Lazure, Mounia Heddad Masson, Alina M. Allen, Jeffrey V. Lazarus, Mazen Noureddin, Mary Rinella, Frank Tacke, Suzanne Murray
Background and AimsNon‐invasive tests (NITs) are underutilized for diagnosis and risk stratification in metabolic dysfunction‐associated steatotic liver disease (MASLD), despite good accuracy. This study aimed to identify challenges and barriers to the use of NITs in clinical practice.MethodsWe conducted a qualitative exploratory study in Germany, Italy, United Kingdom and United States. Phase 1 participants
-
Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes Liver Int. (IF 6.7) Pub Date : 2024-04-18 Marta Garcia‐Guix, Alba Ardevol, Victor Sapena, Edilmar Alvarado‐Tápias, Anna Huertas, Anna Brujats, Javier Fajardo, Berta Cuyas, María Poca, Carlos Guarner, Xavier Torras, Àngels Escorsell, Càndid Villanueva
Background and AimsDecompensated‐cirrhosis encompasses several stages with different prognosis, such as bleeding, ascites and bleeding‐plus‐ascites. Development of further‐decompensation worsens survival, while non‐selective β‐blockers (NSBBs) can modify the risk. However, how this applies to each stage is uncertain. We aimed to investigate, in each stage of decompensated‐cirrhosis, the influence of
-
Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease? Liver Int. (IF 6.7) Pub Date : 2024-04-16 Guillaume Henin, Audrey Loumaye, Louise Deldicque, Isabelle A. Leclercq, Nicolas Lanthier
Myosteatosis is highly prevalent in metabolic dysfunction‐associated steatotic liver disease (MASLD) and could reciprocally impact liver function. Decreasing muscle fat could be indirectly hepatoprotective in MASLD. We conducted a review to identify interventions reducing myosteatosis and their impact on liver function. Non‐pharmacological interventions included diet (caloric restriction or lipid enrichment)
-
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score Liver Int. (IF 6.7) Pub Date : 2024-04-15 Alessio Gerussi, Claudio Cappadona, Davide Paolo Bernasconi, Laura Cristoferi, Maria Grazia Valsecchi, Marco Carbone, Pietro Invernizzi, Rosanna Asselta
Genetic variants influence primary biliary cholangitis (PBC) risk. We established and tested an accurate polygenic risk score (PRS) using these variants.
-
Case‐based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management Liver Int. (IF 6.7) Pub Date : 2024-04-15 Manisha Balwani, Siobán Keel, Peter Meissner, Mark Sonderup, Penelope Stein, Makiko Yasuda
The acute hepatic porphyrias (AHPs) include three autosomal dominant disorders, acute intermittent porphyria, variegate porphyria and hereditary coproporphyria, and the ultra‐rare autosomal recessive 5‐aminolevulinic acid dehydratase‐deficient porphyria. All four are characterized by episodic acute neurovisceral attacks that can be life‐threatening if left untreated. The attacks are precipitated by
-
Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study Liver Int. (IF 6.7) Pub Date : 2024-04-15 Jaekyung Cheon, Sanghoon Jung, Jung Sun Kim, Beodeul Kang, Hyeyoung Kim, Landon L. Chan, Lars Becker, Vincent E. Gaillard, Stephen L. Chan, Chan Kim, Hong Jae Chon
Background and AimsAnti‐programmed death 1 (PD‐1) monotherapy triggers various responses by each organ. In advanced hepatocellular carcinoma (HCC), while extrahepatic lesions demonstrate objective response rates (ORR) of 20%–40%, only 10% of intrahepatic lesions respond. Although first‐line atezolizumab/bevacizumab has shown survival benefits in advanced HCC, organ‐specific responses remain unexplored
-
Targeted inhibition of autophagy in hepatic stellate cells by hydroxychloroquine: An effective therapeutic approach for the treatment of liver fibrosis Liver Int. (IF 6.7) Pub Date : 2024-04-12 Li‐Shuang Hou, Xiao‐Pei Zhai, Yao‐Wen Zhang, Jie‐Hua Xing, Chen Li, Si‐Yuan Zhou, Xiao‐Hong Zhu, Bang‐Le Zhang
Background and PurposeLiver fibrosis is a wound‐healing reaction which is the main cause of chronic liver diseases worldwide. The activated hepatic stellate cell (aHSC) is the main driving factor in the development of liver fibrosis. Inhibiting autophagy of aHSC can prevent the progression of liver fibrosis, but inhibiting autophagy of other liver cells has opposite effects. Hence, targeted inhibition
-
Loss of GCN5L1 exacerbates damage in alcoholic liver disease through ferroptosis activation Liver Int. (IF 6.7) Pub Date : 2024-04-10 Chenxi Yang, Ye Yang, Xiuya Hu, Qiqi Tang, Jiaqi Zhang, Peiyu Zhang, Xin Lu, Juan Xu, Sai Li, Zhengni Dong, Lu Zhu, Lingdi Wang
Background and AimsIron overload, oxidative stress and ferroptosis are associated with liver injury in alcohol‐associated liver disease (ALD), however, the crosstalk among these regulatory pathways in ALD development is unclear.MethodsALD mouse model and general control of amino acid synthesis 5 like 1 (GCN5L1) liver knockout mice were generated to investigate the role of GCN5L1 in ALD development
-
Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence Liver Int. (IF 6.7) Pub Date : 2024-04-10 Stefano Ciardullo, Alessandro Mantovani, Mario Luca Morieri, Emanuele Muraca, Pietro Invernizzi, Gianluca Perseghin
A recent Delphi consensus proposed a new definition for metabolic dysfunction associated steatotic liver disease (MASLD) and introduced a disease entity called MetALD, a condition in which steatotic liver disease (SLD), metabolic dysfunction and moderate alcohol intake coexist. Given the limited available data on the prognostic implications of these disease entities, we performed a systematic review
-
CACS, CCTA and mCAD‐LT score in the pre‐transplant assessment of coronary artery disease and the prediction of post‐transplant cardiovascular events Liver Int. (IF 6.7) Pub Date : 2024-04-09 Giulia Pagano, Lydia Sastre, Annabel Blasi, Salvatore Brugaletta, Judit Mestres, Julia Martinez‐Ocon, Jose T. Ortiz‐Pérez, Clara Viñals, Susanna Prat‐Gonzàlez, Eva Rivas, Rosario J. Perea, Sergio Rodriguez‐Tajes, África Muxí, Emilio Ortega, Ada Doltra, Pablo Ruiz, Bàrbara Vidal, Graciela Martínez‐Palli, Jordi Colmenero, Gonzalo Crespo
BackgroundThe optimal cardiovascular assessment of liver transplant (LT) candidates is unclear. We aimed to evaluate the performance of CT‐based coronary tests (coronary artery calcium score [CACS] and coronary CT angiography [CCTA]) and a modification of the CAD‐LT score (mCAD‐LT, excluding family history of CAD) to diagnose significant coronary artery disease (CAD) before LT and predict the incidence
-
Prognosis algorithms for acute decompensation of cirrhosis and ACLF Liver Int. (IF 6.7) Pub Date : 2024-04-09 Shantha R. Valainathan, Qing Xie, Vicente Arroyo, Pierre‐Emmanuel Rautou
Accurate prediction of survival in patients with cirrhosis is crucial, as patients who are unlikely to survive in the short‐term need to be oriented to liver transplantation and to novel therapeutic approaches. Patients with acute decompensation of cirrhosis without or with organ dysfunction/failure, the so‐called acute‐on‐chronic liver failure (ACLF), have a particularly high short‐term mortality
-
Macrophage activation markers are associated with infection and mortality in patients with acute liver failure Liver Int. (IF 6.7) Pub Date : 2024-04-08 Anna Cavazza, Evangelos Triantafyllou, Roberto Savoldelli, Salma Mujib, Ellen Jerome, Francesca M. Trovato, Florent Artru, Roosey Sheth, Xiao Hong Huang, Yun Ma, Francesco Dazzi, Tasneem Pirani, Charalambos G. Antoniades, William M. Lee, Mark J. McPhail, Constantine J. Karvellas
Acute liver failure is a multisystem disorder with a high mortality and frequent need for emergency liver transplantation. Following massive innate immune system activation, soluble markers of macrophage activation are released during liver damage and their association with disease severity and prognosis requires exploration.
-
Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort Liver Int. (IF 6.7) Pub Date : 2024-04-08 Antoine Lebeaud, Leony Antoun, Jane‐Rose Paccard, Julien Edeline, Hélène Bourien, Nadim Fares, Christophe Tournigand, Thierry Lecomte, David Tougeron, Vincent Hautefeuille, Angélique Viénot, Julie Henriques, Nicolas Williet, Jean‐Baptiste Bachet, Cristina Smolenschi, Antoine Hollebecque, Teresa Macarulla, Florian Castet, David Malka, Cindy Neuzillet, Dewi Vernerey, Alice Boilève, Anthony Turpin
Background & AimsAccumulating data has shown the rising incidence and poor prognosis of early‐onset gastrointestinal cancers, but few data exist on biliary tract cancers (BTC). We aimed to analyse the clinico‐pathological, molecular, therapeutic characteristics and prognosis of patients with early onset BTC (EOBTC, age ≤50 years at diagnosis), versus olders.MethodsWe analysed patients diagnosed with
-
Upfront multi‐bipolar radiofrequency ablation for HCC in transplant‐eligible cirrhotic patients with salvage transplantation in case of recurrence Liver Int. (IF 6.7) Pub Date : 2024-04-06 Carina Boros, Olivier Sutter, François Cauchy, Nathalie Ganne‐Carrié, Pierre Nahon, Gisele N'kontchou, Marianne Ziol, Véronique Grando, Alix Demory, Lorraine Blaise, Fédérica Dondero, François Durand, Olivier Soubrane, Mickael Lesurtel, Alexis Laurent, Oliver Seror, Jean Charles Nault
IntroductionWe aim to assess the long‐term outcomes of percutaneous multi‐bipolar radiofrequency (mbpRFA) as the first treatment for hepatocellular carcinoma (HCC) in transplant‐eligible cirrhotic patients, followed by salvage transplantation for intrahepatic distant tumour recurrence or liver failure.Materials and MethodsWe included transplant‐eligible patients with cirrhosis and a first diagnosis
-
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH—An individual participant data meta-analysis Liver Int. (IF 6.7) Pub Date : 2024-04-04 Ferenc E. Mózes, Jenny A. Lee, Yasaman Vali, Emmanuel A. Selvaraj, Arjun N. A. Jayaswal, Jérôme Boursier, Victor de Lédinghen, Monica Lupșor-Platon, Yusuf Yilmaz, Wah-Kheong Chan, Sanjiv Mahadeva, Thomas Karlas, Johannes Wiegand, Shalimar, Emmanouil Tsochatzis, Antonio Liguori, Vincent Wai-Sun Wong, Dae Ho Lee, Adriaan G. Holleboom, Anne-Marieke van Dijk, Anne Linde Mak, Hannes Hagström, Camilla Akbari
There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) in clinical practice. We aimed to evaluate non-invasive tests (NITs) screening approaches for these target conditions.
-
Changing landscape of alcohol‐associated liver disease in younger individuals, women, and ethnic minorities Liver Int. (IF 6.7) Pub Date : 2024-04-05 Juan P Arab, Winston Dunn, Gene Im, Ashwani K. Singal
Alcohol use is the most important determinant of the development of alcohol‐associated liver disease (ALD) and of predicting long‐term outcomes in those with established liver disease. Worldwide, the amount, type, and pattern of use of alcohol vary. Alcohol use and consequent liver disease have been increasing in certain ethnic groups especially Hispanics and Native Americans, likely due to variations
-
The first MASH drug therapy on the horizon: Current perspectives of resmetirom Liver Int. (IF 6.7) Pub Date : 2024-04-05 Salvatore Petta, Giovanni Targher, Stefano Romeo, Utpal B. Pajvani, Ming‐Hua Zheng, Alessio Aghemo, Luca V. C. Valenti
The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD is linked to increased mortality rates and substantial healthcare costs, primarily driven by its progression to metabolic dysfunction‐associated steatohepatitis (MASH), which can lead to severe liver complications including
-
Relationship between Helicobacter pylori infection and risk of metabolic dysfunction‐associated steatotic liver disease: An updated meta‐analysis Liver Int. (IF 6.7) Pub Date : 2024-04-03 Alessandro Mantovani, Maria Giovanna Lando, Nicolò Borella, Enrico Scoccia, Barbara Pecoraro, Federico Gobbi, Zeno Bisoffi, Luca Valenti, Herbert Tilg, Christopher D. Byrne, Giovanni Targher
BackgroundRecent observational studies examining the association between Helicobacter pylori infection and the risk of metabolic dysfunction‐associated steatotic liver disease (MASLD) have reported conflicting results. We performed a meta‐analysis to quantify the magnitude of the association between H. pylori infection and the risk of MASLD.MethodsWe systematically searched three large electronic databases
-
Histological characterization of liver involvement in systemic mastocytosis Liver Int. (IF 6.7) Pub Date : 2024-03-30 Julien Rossignol, Danielle Canioni, Achille Aouba, Cristina Bulai-Livideanu, Stéphane Barete, Charles Lancesseur, Laura Polivka, Marine Madrange, Thomas Ballul, Antoine Neuraz, Celine Greco, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Clément Gourguechon, Laurent Frenzel, Cécile Meni, Caroline Gaudy-Marqueste,
Systemic mastocytosis (SM) is characterized by the accumulation of atypical mast cells (MCs) in organs. Liver histology of SM has been marginally described and accurate histological classification is critical, given the consequences of aggressive SM diagnosis. We aimed to describe the histological features associated with liver SM using updated tools.
-
Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta‐analysis Liver Int. (IF 6.7) Pub Date : 2024-04-02 Robert J. Wong, Carol Brosgart, Steven S. Wong, Jordan Feld, Jeffrey Glenn, Saeed Hamid, Chari Cohen, Beatrice Zovich, John Ward, Heiner Wedemeyer, Cihan Yurdaydin, Robert Gish
Background and AimsSuboptimal awareness and low rates of hepatitis delta virus (HDV) testing contribute to underdiagnosis and gaps in accurate estimates of U.S. HDV prevalence. We aim to provide an updated assessment of HDV prevalence in the U.S. using a comprehensive literature review and meta‐analysis approach.MethodsA comprehensive literature review of articles reporting HBsAg seroprevalence and
-
Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction–associated steatotic liver disease Liver Int. (IF 6.7) Pub Date : 2024-04-01 Takashi Kumada, Hidenori Toyoda, Sadanobu Ogawa, Tatsuya Gotoh, Yasuaki Suzuki, Katsutoshi Sugimoto, Yuichi Yoshida, Hidekatsu Kuroda, Yoshihiro Kamada, Yoshio Sumida, Takanori Ito, Tomoyuki Akita, Junko Tanaka
Background & AimsThe predictors of progression from steatosis to more advanced stages of metabolic dysfunction–associated steatotic liver disease (MASLD) remain unclear. We evaluated the association between the quantity of hepatic steatosis and longitudinal changes in liver stiffness measurements (LSMs) using magnetic resonance elastography (MRE) in patients with MASLD.MethodsWe retrospectively analysed
-
Liver stiffness predicts progression to liver‐related events in patients with chronic liver disease – A cohort study of 14 414 patients Liver Int. (IF 6.7) Pub Date : 2024-04-01 Hannes Hegmar, Axel Wester, Soo Aleman, Jens Backman, Erik Degerman, Håkan Ekvall, Katarina Lund, Åsa Lundgren, Patrik Nasr, Afshin Shahnavaz, Johan Vessby, Johan Westin, Kristina Önnerhag, Hannes Hagström
Background & AimsLiver stiffness measurement (LSM) by vibration‐controlled transient elastography (VCTE) is a non‐invasive diagnostic biomarker of liver fibrosis. It is uncertain if LSM can predict risk for future liver‐related outcomes in large, heterogenous populations.MethodsThis Swedish multi‐centre cohort study included patients (n = 14 414) from 16 sites who underwent LSM by VCTE between 2008
-
Shining a spotlight on sarcopenia and myosteatosis in liver disease and liver transplantation Liver Int. (IF 6.7) Pub Date : 2024-03-30 Sophie Reichelt, Uta Merle, Miriam Klauss, Christoph Kahlert, Georg Lurje, Arianeb Mehrabi, Zoltan Czigany
Muscle‐wasting and disease‐related malnutrition are highly prevalent in patients with chronic liver diseases (CLD) as well as in liver transplant (LT) candidates. Alterations of body composition (BC) such as sarcopenia, myosteatosis and sarcopenic obesity and associated clinical frailty were tied to inferior clinical outcomes including hospital admissions, length of stay, complications, mortality and
-
FGF21 protects against ischaemia reperfusion injury in normal and fatty livers Liver Int. (IF 6.7) Pub Date : 2024-03-30 Yong Ma, Garima Singhal, Suzanne S. Chan, Chaoqun Wang, Hongjun Yu, Bing Yin, Jing Pang, Grace Malvar, Imad Nasser, Marie L. Mather, Eleftheria Maratos‐Flier
BackgroundLiver ischaemia/reperfusion (I/R) injury, which is an inevitable clinical problem of liver resection, liver transplantation and haemorrhagic shock. Fibroblast growth factor 21 (FGF21) was intimately coupled with multiple metabolic processes and proved to protect against apoptosis and inflammatory response in hepatocytes during hepatic I/R injury. However, the regulatory mechanisms of FGF21
-
Neurokinin‐1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma Liver Int. (IF 6.7) Pub Date : 2024-03-30 Yang Yang, Xueyan Cao, Yuting Wang, Xinyu Wu, Ping Zhou, Lin Miao, Xueting Deng
BackgroundIntrahepatic cholangiocarcinoma (iCCA) has a poor prognosis and limited treatment options. Aprepitant, a selective NK‐1R antagonist, can inhibit the growth of various tumours in vitro and in vivo. However, it remains unclear whether aprepitant has cytotoxic effects on iCCA.MethodsWe measured the expression of SP/NK‐1R in clinical samples of iCCA by immunohistochemistry. Then, we detected
-
Excessive fatty acids activate PRMT5/MDM2/Drosha pathway to regulate miRNA biogenesis and lipid metabolism Liver Int. (IF 6.7) Pub Date : 2024-03-22 Aijun Hou, Xiaoding Xu, Yu Zhang, Hongxiu He, Yihan Feng, Wenhui Fan, Rongrong Tan, Likun Gong, Jing Chen
BackgroundExcessive fatty acids in the liver lead to the accumulation of lipotoxic lipids and then cellular stress to further evoke the related disease, like non‐alcoholic fatty liver disease (NAFLD). As reported, fatty acid stimulation can cause some specific miRNA dysregulation, which caused us to investigate the relationship between miRNA biogenesis and fatty acid overload.MethodsGene expression
-
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab Liver Int. (IF 6.7) Pub Date : 2024-03-22 Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Fabian Finkelmeier, Changhoon Yoo, José Presa, Elisabeth Amadeo, Virginia genovesi, Maria Caterina De Grandis, Massimo Iavarone, Fabio Marra, Francesco Foschi, Emiliano Tamburini, Federico Rossari, Francesco Vitiello, Linda Bartalini, Caterina Soldà, Francesco Tovoli, Caterina Vivaldi, Sara Lonardi, Marianna
IntroductionOverweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment.Methods and
-
-
Prognostic stratification in early‐stage hepatocellular carcinoma: Imaging biomarkers are needed Liver Int. (IF 6.7) Pub Date : 2024-03-22 Jérémy Dana, Olivier Sutter
Early-stage hepatocellular carcinoma (HCC), defined as a single tumour (stage 0 if ≤2 cm; stage A if >2 cm) or ≤3 tumours ≤3 cm (stage A) as per the Barcelona Clinic Liver Cancer (BCLC) classification,1 is eligible for curative treatment including liver transplantation, surgical resection, and percutaneous ablation. Although percutaneous ablation has been shown to offer overall survival rates comparable
-
ENPP2/Autotaxin: The potential drug target for alcoholic liver disease identified through Mendelian randomization analysis Liver Int. (IF 6.7) Pub Date : 2024-03-22 Peiqiong Luo, Xuefeng Yu
Background and AimsAt present, there is still a lack of radical drug targets for intervention in alcoholic liver disease (ALD), and drug discovery through randomized controlled trials is a lengthy, risky, and expensive undertaking, so we aimed to identify effective drug targets based on human genetics.MethodsWe used Mendelian randomization (MR) and Bayesian colocalization analysis to investigate 2639
-
Profiling plasma alterations of extracellular vesicles in patients with acutely decompensated cirrhosis and bacterial infection Liver Int. (IF 6.7) Pub Date : 2024-03-22 Elena Campello, Alberto Zanetto, Claudia M. Radu, Serena Toffanin, Sarah Shalaby, Sabrina Gavasso, Stefania Rizzo, Nicola Perin, Paolo Angeli, Patrizia Burra, Marco Senzolo, Paolo Simioni
BackgroundExtracellular vesicles (EVs) modulate inflammation, coagulation and vascular homeostasis in decompensated cirrhosis.AimTo characterize the profile of plasmatic EVs in patients with decompensated cirrhosis and bacterial infections and evaluate the association between EVs and the development of hemostatic complications.MethodsWe measured the levels of EVs using high‐sensitivity flow cytometry
-
Sex differences in mortality and liver‐related events in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis Liver Int. (IF 6.7) Pub Date : 2024-03-20 Huimin Zhou, Haiyan Chen, Hanxiao Lu, Bo Wu, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang
Background & AimsMany systematic reviews explore the association of non‐alcoholic fatty liver disease (NAFLD) with mortality, but none of them explores sex‐based differences in detail. We aimed to assess whether NAFLD is associated with cause‐specific mortality, all‐cause mortality, and cancer incidence in both men and women.MethodsThe PubMed, Embase, and Medline databases were searched from inception
-
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab Liver Int. (IF 6.7) Pub Date : 2024-03-16 Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, Kazuya Kariyama, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Toshifumi Tada, Tetsuya Yasunaka, Masahiro Sakata, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki, Motoyuki Otsuka
BackgroundTo identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC).MethodsIn total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first‐line chemotherapy, were studied. Patients who achieved complete
-
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Liver Int. (IF 6.7) Pub Date : 2024-03-16 Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi
BackgroundThe prognosis of metabolic dysfunction‐associated steatotic liver disease (MASLD) is associated with liver fibrosis. We investigated the associations between changes in liver stiffness measurement (LSM) over 3‐year period and the development of cirrhosis or hepatocellular carcinoma (HCC) in patients with MASLD.MethodsThis study involved patients with MASLD who underwent transient elastography
-
An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial Liver Int. (IF 6.7) Pub Date : 2024-03-14 Ang Huang, Yun Zhu, Shuhong Liu, Ying Sun, Zherui Liu, Qing‐sheng Liang, Jun Zhao, Bin‐xia Chang, Jing‐feng Bi, Jiang‐tao Liu, Xing‐ran Zhai, Huan Xie, Ning Li, Hui Tian, Lin Han, Yingjie Zhuang, Hongbin Ma, Guang‐ju Teng, Wei Zhang, Guruprasad P. Aithal, Dong Ji, Jingmin Zhao, Zhengsheng Zou
Background and AimsThe use of corticosteroids in chronic drug‐induced liver injury (DILI) is an important issue. Our previous randomized controlled trial showed that patients with chronic DILI benefited from a 48‐week steroid stepwise reduction (SSR) regimen. However, it remains unclear whether a shorter course of therapy can achieve similar efficacy. In this study, we aimed to assess whether a 36‐week
-
Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes Liver Int. (IF 6.7) Pub Date : 2024-03-08 Huey‐Ling Chen, Chien‐Nan Lee, Chin‐Hao Chang, Ming‐Wei Lai, Ming‐Chieh Tsai, Shu‐Chi Mu, Chun‐Jen Liu, Jin‐Chung Shih, Wan‐Hsin Wen, Rui‐Ting Hu, Chun‐Pin Huang, Kuang‐Chun Hu, Chie‐Pein Chen, Chyi‐Long Lee, Rong‐Nan Chien, Kai‐Chi Chang, Hong‐Yuan Hsu, Chien‐Chang Lee, Yen‐Hsuan Ni, Mei‐Hwei Chang
BackgroundThe use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother‐to‐child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation.MethodsThe maternal and infant outcomes were compared
-
Proactive case finding of alcohol‐related liver disease in high‐risk populations: A systematic review Liver Int. (IF 6.7) Pub Date : 2024-03-08 Ann J. Archer, Jennifer Phillips, Mohsan Subhani, Zoe Ward, Fiona H. Gordon, Matthew Hickman, Ashwin D. Dhanda, Kushala W. M. Abeysekera
BackgroundAlcohol‐related liver disease (ARLD) is often diagnosed at a late stage when mortality is unacceptably high. Earlier identification of ARLD may lead to reduced alcohol intake, participation in hepatocellular carcinoma surveillance and reduction in liver‐related morbidity and mortality. People with alcohol use disorder (AUD) are at highest risk of ARLD. The aim of this systematic review was
-
Liver transplantation and primary liver cancer in porphyria Liver Int. (IF 6.7) Pub Date : 2024-03-08 Mattias Lissing, Bruce Wang, Staffan Wahlin
The porphyrias are a heterogeneous group of metabolic disorders that result from defects in heme synthesis. The metabolic defects are present in all cells, but symptoms are mainly cutaneous or related to neuropathy. The porphyrias are highly relevant to hepatologists since patients can present with symptoms and complications that require liver transplantation (LT), and some porphyrias are associated
-
Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA—Update with genetic correlations Liver Int. (IF 6.7) Pub Date : 2024-03-07 Herbert L. Bonkovsky, Marwan Ghabril, Paola Nicoletti, Andrew Dellinger, Robert J. Fontana, Huiman Barnhart, Jiezhun Gu, Ann K. Daly, Guruprasad P. Aithal, Elizabeth J. Phillips, David E. Kleiner
To describe patients with NSAID-DILI, including genetic factors associated with idiosyncratic DILI.
-
Hepatic organoids move from adolescence to maturity Liver Int. (IF 6.7) Pub Date : 2024-03-07 Yuan Guan, Gary Peltz
Since organoids were developed 15 years ago, they are now in their adolescence as a research tool. The ability to generate ‘tissue in a dish’ has created enormous opportunities for biomedical research. We examine the contributions that hepatic organoids have made to three areas of liver research: as a source of cells and tissue for basic research, for drug discovery and drug safety testing, and for
-
Recipient age influences survival after liver transplant: Results of the French national cohort 2007–2017 Liver Int. (IF 6.7) Pub Date : 2024-03-07 Lea Lerosey, Elea Ksiasek, Michal Abrahamowicz, Corinne Antoine, Sébastien Dharancy, Jérôme Dumortier, Alexandre Doussot, Vincent Di Martino, Pauline Houssel‐Debry, Filomena Conti, Claire Francoz, Georges‐Philippe Pageaux, Ephrem Salame, François Faitot, Audrey Coilly, Jean Hardwigsen, Thomas Decaens, Faiza Chermak, Fabrice Muscari, Rodolphe Anty, Christophe Duvoux, Armand Abergel, Anne Minello, Thomas
BackgroundIn recent years, age at liver transplantation (LT) has markedly increased. In the context of organ shortage, we investigated the impact of recipient age on post‐transplantation mortality.MethodsAll adult patients who received a first LT between 2007 and 2017 were included in this cross‐sectional study. Recipients' characteristics at the time of listing, donor and surgery data, post‐operative
-
Impact of new direct‐acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection Liver Int. (IF 6.7) Pub Date : 2024-03-06 Farinaz Forouzannia, Abdullah Hamadeh, Ana Maria Passos‐Castilho, Aysegul Erman, Amanda Yu, Zeny Feng, Naveed Z. Janjua, Beate Sander, Christina Greenaway, William W. L. Wong
BackgroundPatients with chronic hepatitis C (CHC) can be cured with the new highly effective interferon‐free combination treatments (DAA) that were approved in 2014. However, CHC is a largely silent disease, and many individuals are unaware of their infections until the late stages of the disease. The impact of wider access to effective treatments and improved awareness of the disease on the number
-
Health information in short videos about metabolic dysfunction‐associated steatotic liver disease: Analysing quality and reliability Liver Int. (IF 6.7) Pub Date : 2024-03-05 Ruihao Ding, Qingzhou Kong, Longfei Sun, Xuyan Liu, Leiqi Xu, Yueyue Li, Xiuli Zuo, Yanqing Li
Background & AimsShort videos, crucial for disseminating health information on metabolic dysfunction‐associated steatotic liver disease (MASLD), lack a clear evaluation of quality and reliability. This study aimed to assess the quality and reliability of MASLD‐related videos on Chinese platforms.MethodsVideo samples were collected from three platforms (TikTok, Kwai and Bilibili) during the period from
-
Multitask deep learning for prediction of microvascular invasion and recurrence‐free survival in hepatocellular carcinoma based on MRI images Liver Int. (IF 6.7) Pub Date : 2024-03-04 Fang Wang, Gan Zhan, Qing‐qing Chen, Hou‐yun Xu, Dan Cao, Yuan‐yuan Zhang, Yin‐hao Li, Chu‐jie Zhang, Yao Jin, Wen‐bin Ji, Jian‐bing Ma, Yun‐jun Yang, Wei Zhou, Zhi‐yi Peng, Xiao Liang, Li‐ping Deng, Lan‐fen Lin, Yen‐wei Chen, Hong‐jie Hu
Background and AimsAccurate preoperative prediction of microvascular invasion (MVI) and recurrence‐free survival (RFS) is vital for personalised hepatocellular carcinoma (HCC) management. We developed a multitask deep learning model to predict MVI and RFS using preoperative MRI scans.MethodsUtilising a retrospective dataset of 725 HCC patients from seven institutions, we developed and validated a multitask
-
Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma Liver Int. (IF 6.7) Pub Date : 2024-03-04 Clémentine Alitti, Agnès Rode, Hervé Trillaud, Philippe Merle, Jean‐Frédéric Blanc, Lorraine Blaise, Alix Demory, Gisele Nkontchou, Véronique Grando, Marianne Ziol, Pierre Nahon, Nathalie Ganne‐Carrié, Arthur Petit, Olivier Seror, Olivier Sutter, Jean‐Charles Nault
IntroductionThe effectiveness of percutaneous radiofrequency ablation (RFA) in intrahepatic cholangiocarcinomas (iCCA) remains insufficiently studied.MethodsWe conducted a retrospective study including patients with histologically proven iCCA within Milan criteria treated by percutaneous RFA from 2000 to 2022. The primary outcome was overall survival in treatment‐naive patients and secondary outcomes
-
Progression pattern and post‐progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma Liver Int. (IF 6.7) Pub Date : 2024-03-04 Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Yoshitaka Arase, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Manabu Morimoto, Shin Maeda
BackgroundAlthough the combination of atezolizumab and bevacizumab (ATZ + BEV) is a standard treatment for advanced hepatocellular carcinoma (HCC), strategies for addressing treatment failure and prognostic factors of post‐progression survival (PPS) remain unestablished.MethodsWe conducted a multicentre retrospective study to evaluate PPS following ATZ + BEV treatment in patients with advanced HCC
-
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma Liver Int. (IF 6.7) Pub Date : 2024-03-01 Edoardo G. Giannini, Andrea Pasta, Giulia Pieri, Maria Corina Plaz Torres, Mariarosaria Marseglia, Filippo Pelizzaro, Angelo Sangiovanni, Giuseppe Cabibbo, Giorgia Ghittoni, Mariella Di Marco, Francesco Giuseppe Foschi, Maria Guarino, Elisabetta Biasini, Carlo Saitta, Claudia Campani, Gianluca Svegliati-Baroni, Antonio Gasbarrini, Maurizia Rossana Brunetto, Donatella Magalotti, Francesco Azzaroli,
Chronic hepatitis D virus (HDV) often leads to end-stage liver disease and hepatocellular carcinoma (HCC). Comprehensive data pertaining to large populations with HDV and HCC are missing, therefore we sought to assess the characteristics, management, and outcome of these patients, comparing them to patients with hepatitis B virus (HBV) infection.
-
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort Liver Int. (IF 6.7) Pub Date : 2024-03-01 Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Pei‐Wu Zhu, Sui‐Dan Chen, Morten Karsdal, Diana Julie Leeming, Pei Jiang, Cong Wang, Qiang Chen, Christopher D. Byrne, Giovanni Targher, Mohammed Eslam, Jacob George, Vincent Wai‐Sun Wong, Ming‐Hua Zheng
BackgroundMetabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N‐terminal propeptide of collagen type 3 (PRO‐C3) is a biomarker of advanced fibrosis in MAFLD and PRO‐C3 may be involved in renal fibrosis. We aimed to use PRO‐C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease
-
Artificial replication cohort: Leveraging AI‐fabricated data for genetic studies Liver Int. (IF 6.7) Pub Date : 2024-03-01 Wiktor Smyk, Krystian Adrych, Marcin Krawczyk
Recent advancements in artificial intelligence (AI) present both opportunities and challenges within the scientific community. This study explores the capability of AI to replicate findings from genetic research, focusing on findings from prior work. Using an AI model without exposing any raw data, we created a dataset that closely mirrors the results of our original study, illustrating the ease of
-
Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030 Liver Int. (IF 6.7) Pub Date : 2024-03-01 Guoqing Ouyang, Guangdong Pan, Qiuyun Li, Shuang Li, Tao Liu, Xiaolei Yi, Zhipeng Liu
Background and AimsAcute hepatitis E (AHE) is still a public health issue worldwide. Here, we report the global burden of AHE in 204 countries and territories from 1990 to 2019 by age, sex and socio‐demographic index (SDI), and predict the future trends to 2030.MethodsData on AHE were collected from the Global Burden of Diseases, Injuries and Risk Factors Study 2019. The average annual percentage change
-
Acute and non‐acute decompensation of liver cirrhosis (47/130) Liver Int. (IF 6.7) Pub Date : 2024-03-01 Martin S. Schulz, Paolo Angeli, Jonel Trebicka
In the traditional view, the occurrence of cirrhosis‐related complications, such as hepatic encephalopathy, formation of ascites or variceal haemorrhage, marks the transition to the decompensated stage of cirrhosis. Although the dichotomous stratification into a compensated and decompensated state reflects a prognostic water‐shed moment and remains to hold its prognostic validity, it represents an
-
Combination of heterozygous APOB gene mutation with PNPLA3 and TM6SF2 variants promotes steatotic liver disease, cirrhosis and HCC development Liver Int. (IF 6.7) Pub Date : 2024-02-29 Yasmina Chouik, Mathilde Di Filippo, Sylvie Radenne, Jérôme Dumortier, Philippe Moulin, Massimo Levrero
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide. In recent years, several single nucleotide polymorphisms (SNPs) in genes involved in hepatic lipid metabolism (PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13) have been shown to significantly contribute to the emergence of the disease in association with environmental factors.1-3 Monogenic disorders
-
-
Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study Liver Int. (IF 6.7) Pub Date : 2024-02-26 Majd B. Aboona, Claire Faulkner, Pooja Rangan, Cheng Han Ng, Daniel Q. Huang, Mark Muthiah, Moises I. Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Donghee Kim, Vincent L. Chen, Karn Wijarnpreecha
BackgroundMetabolic dysfunction‐associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease and 10%–20% occurs in lean individuals. There is little data in the literature regarding outcomes in an ethnically‐diverse patient populations with MASLD. Thus, we aim to investigate the natural history and ethnic disparities of MASLD patients in a diverse population, and stratified
-
Plastic compounds and liver diseases: Whether bisphenol A is the only culprit Liver Int. (IF 6.7) Pub Date : 2024-02-26 Sonal Sangwan, Rajasri Bhattacharyya, Dibyajyoti Banerjee
Plastics, while providing modern conveniences, have become an inescapable source of global concern due to their role in environmental pollution. Particularly, the focus on bisphenol A (BPA) reveals its biohazardous nature and association with liver issues, specifically steatosis. However, research indicates that BPA is just one facet of the problem, as other bisphenol analogues, microplastics, nanoplastics